← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Gismo Therapeutics, Inc.
Howard Beach, NY
$5,661,712
Total funding
4
Grants
Funding over time
peak $1.2M · FY2013–24$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,661,712 · 4
By mechanism
R44$4,855,452 · 1
R43$806,260 · 3
Investigators at Gismo Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Amyloid-Beta and Tau/Glycosaminoglycan Dual Inhibitor for Alzheimer's Disease$1,192,768
R44 · FY2024 · AG
Amyloid-Beta and Tau/Glycosaminoglycan Dual Inhibitor for Alzheimer's Disease$983,932
R44 · FY2022 · AG
Glycosaminoglycan-Interacting Small Molecule (GISMO) as Alzheimer's Therapeutics$952,480
R44 · FY2018 · AG
Glycosaminoglycan-Interacting Small Molecule (GISMO) as Alzheimer's Therapeutics$933,415
R44 · FY2017 · AG
Amyloid-Beta and Tau/Glycosaminoglycan Dual Inhibitor for Alzheimer's Disease$792,857
R44 · FY2023 · AG
Glycosaminoglycan-Interacting Small Molecule (GISMO) as Parkinson's Therapeutic$241,938
R43 · FY2016 · NS
Glycosaminoglycan-Cytokine Inhibitors for Arthritis Therapy$224,997
R43 · FY2015 · AR
Glycosaminoglycan Interacting Small Molecules (GISMO) as Novel AD Therapeutics$197,137
R43 · FY2013 · AG
Glycosaminoglycan-Interacting Small Molecule (GISMO) as Parkinson's Therapeutic$142,188
R43 · FY2017 · NS